Crescent Biopharma (CBIO)
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which i...
- Open
- 17.780
- High
- 18.000
- Low
- 17.020
- Prev. Close
- 17.760
- Volume
- 149.15K
- Turnover
- 2.64M
- Avg Price
- 17.691
- Bid/Ask Ratio
- --
- Amplitude
- 5.52%
- 52wk High
- 27.410
- Volume Ratio
- 0.30
- Turnover Ratio
- 0.90%
Crescent Biopharma Analyst Rating
View moreForecast & Rating
Aug 26, 2026Price forecast
$30.6072.39%
Forecast & RatingStrong buy
8analysts
- Strong buy75.00%
- Buy12.50%
- Hold12.50%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · 2 days ago, 08:36 AM
Wedbush Reiterates "Outperform" Rating for Crescent Biopharma (NASDAQ:CBIO)
- Market Beat · Aug 26 at 10:40 AM
Crescent Biopharma (NASDAQ:CBIO) Trading Up 4.2% - Time to Buy?
- Global Report · Aug 25 at 05:12 AM
TikTok stars, AI pivots and a $125M buyout: The identity crisis of fringe stocks
- Earnings Watch · Aug 7 at 07:02 AM
Crescent Biopharma | 8-K: FY2026 Q2 Revenue: USD 29.11 M
- PUBT · Aug 3 at 06:35 AM
Crescent Biopharma grants employee stock options for 19,425 shares at $14.47 each
- Tip Ranks · Jul 31 at 10:48 AM
Crescent Biopharma (CBIO) Gets a Buy from Wedbush
